{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:42:47Z","timestamp":1789756967393,"version":"4.0.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.2215\/cjn.07050714","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T22:32:04Z","timestamp":1429741924000},"page":"1031-1040","source":"Crossref","is-referenced-by-count":75,"title":["A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)"],"prefix":"10.2215","volume":"10","author":[{"given":"James B.","family":"Wetmore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Gurevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Da Roza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Buerkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20230601","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-18-20230601","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","article-title":"Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.","volume":"23","author":"Block","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R3-18-20230601","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2215\/CJN.00870805","article-title":"Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.","volume":"1","author":"Chertow","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-18-20230601","doi-asserted-by":"crossref","first-page":"c124","DOI":"10.1159\/000345164","article-title":"Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.","volume":"121","author":"Cooper","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"R5-18-20230601","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results.","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-18-20230601","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study.","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R7-18-20230601","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: Assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism.","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R8-18-20230601","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"R9-18-20230601","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5414\/CNP68010","article-title":"Cinacalcet HCI (Sensipar\/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism.","volume":"68","author":"Sterrett","year":"2007","journal-title":"Clin Nephrol"},{"key":"R10-18-20230601","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","article-title":"Cinacalcet and achievement of the NKF\/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice\u2014the ECHO observational study.","volume":"24","author":"Ure\u00f1a","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R11-18-20230601","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.","volume":"36","author":"Fraz\u00e3o","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R12-18-20230601","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/ki.2011.226","article-title":"No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: A randomized crossover trial.","volume":"80","author":"Hansen","year":"2011","journal-title":"Kidney Int"},{"key":"R13-18-20230601","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study.","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R14-18-20230601","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R15-18-20230601","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"R16-18-20230601","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"R17-18-20230601","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney Int"},{"key":"R19-18-20230601","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.semnephrol.2004.06.006","article-title":"Calcimimetic agents for the treatment of secondary hyperparathyroidism.","volume":"24","author":"Goodman","year":"2004","journal-title":"Semin Nephrol"},{"key":"R20-18-20230601","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study.","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"R21-18-20230601","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1681\/ASN.2004080657","article-title":"Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans.","volume":"16","author":"Ca\u00f1adillas","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R22-18-20230601","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1523-1755.2002.kid585.x","article-title":"Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism.","volume":"62","author":"Tokumoto","year":"2002","journal-title":"Kidney Int"},{"key":"R23-18-20230601","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/j.1523-1755.2005.310_1.x","article-title":"High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism.","volume":"67","author":"Touam","year":"2005","journal-title":"Kidney Int"},{"key":"R24-18-20230601","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1053\/j.ajkd.2011.08.033","article-title":"Effect of dialysate calcium concentrations on parathyroid hormone and calcium balance during a single dialysis session using bicarbonate hemodialysis: A crossover clinical trial.","volume":"59","author":"Basile","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R26-18-20230601","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ndt\/gfl560","article-title":"Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.","volume":"22","author":"Serra","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R27-18-20230601","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","article-title":"Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.","volume":"28","author":"Ure\u00f1a-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R28-18-20230601","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ckj\/sft026","article-title":"Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction.","volume":"6","author":"Zitt","year":"2013","journal-title":"Clin Kidney J"},{"key":"R29-18-20230601","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfu011","article-title":"Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: Results of the IMPACT-SHPT study.","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R30-18-20230601","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int"},{"key":"R31-18-20230601","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"R32-18-20230601","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1210\/jc.2012-3246","article-title":"Calcium-mediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients.","volume":"98","author":"Rodriguez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-18-20230601","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1681\/ASN.V112330","article-title":"Race is a major determinant of secondary hyperparathyroidism in uremic patients.","volume":"11","author":"Gupta","year":"2000","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201506000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:20Z","timestamp":1786369520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201506000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.07050714","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}